|
|||
| |||||||||||||||||||||||||||||||||||||||||||
Indeed, apart from important advances in preventing mother-to-child transmission, primarily through the use of antiretroviral drugs, and in preventing the acquisition of HIV in men by means of circumcision, only one late-stage randomized biomedical trial — involving
Source Information
Dr. Lagakos is a professor of biostatistics at the Harvard School of Public Health, Boston, and a statistical consultant to the Journal. Ms. Gable is a senior program officer at the IOM, Washington, DC. Dr. Lagakos was the chair, and Ms. Gable the study director, of the IOM Committee on Methodological Challenges in Biomedical HIV Prevention Trials; the other committee members were as follows: Dr. Harvey J. Alter, National Institutes of Health; Dr. Ronald Bayer, Columbia University; Dr. Solomon R. Benatar, University of Cape Town; Dr. Ronald S. Brookmeyer, Johns Hopkins University; Dr. Carlos Del Rio, Emory University; Dr. David W. Feigal, Elan Pharmaceuticals; Dr. Els Goetghebeur, Ghent University; Dr. Laura A. Guay, Johns Hopkins University; Dr. Sally L. Hodder, University of Medicine and Dentistry of New Jersey; Dr. Shabbar Jaffar, London School of Hygiene and Tropical Medicine; Dr. Edward K. Kurumira, Makerere University; Dr. George W. Rutherford, University of California, San Francisco; Dr. Olive Shisana, South African Human Sciences Research Council; and Dr. Gina Wingood, Emory University.
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |